Across TCGA pan-cancer cohorts, RPTN mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated RPTN data layer compared with 18 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher RPTN mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RPTN expression acts as an unfavorable survival marker, although some lineages such as HNSC and PDAC show a favorable association.

HNSC and PDAC are the cancer types where RPTN mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Quartile	All	0.775	0.498	.012	18	view →
PDAC	DFS	Tertile	II,III,IV	0.633	0.260	.047	4	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: RPTN tumor-vs-normal RNA expression · all RPTN data types